ES2528469T3 - Uso de oligosacáridos que contienen N-acetil-lactosamida para la maduración de las respuestas inmunes en neonatos - Google Patents
Uso de oligosacáridos que contienen N-acetil-lactosamida para la maduración de las respuestas inmunes en neonatos Download PDFInfo
- Publication number
- ES2528469T3 ES2528469T3 ES08848466.2T ES08848466T ES2528469T3 ES 2528469 T3 ES2528469 T3 ES 2528469T3 ES 08848466 T ES08848466 T ES 08848466T ES 2528469 T3 ES2528469 T3 ES 2528469T3
- Authority
- ES
- Spain
- Prior art keywords
- lacto
- infant
- young
- octaose
- para
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001542 oligosaccharide Polymers 0.000 title abstract 2
- 150000002482 oligosaccharides Chemical class 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title 1
- 230000035800 maturation Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 235000016709 nutrition Nutrition 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- PDWGIAAFQACISG-QZBWVFMZSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O PDWGIAAFQACISG-QZBWVFMZSA-N 0.000 abstract 1
- NPPRJALWPIXIHO-PNCMPRLYSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NPPRJALWPIXIHO-PNCMPRLYSA-N 0.000 abstract 1
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 abstract 1
- UTVHXMGRNOOVTB-IXBJWXGWSA-N beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O UTVHXMGRNOOVTB-IXBJWXGWSA-N 0.000 abstract 1
- 244000005709 gut microbiome Species 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 abstract 1
- -1 lacto-Nneotetraose Chemical compound 0.000 abstract 1
- ZDZMLVPSYYRJNI-CYQYEHMMSA-N p-lacto-n-hexaose Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1N=C(C)O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)OC([C@@H]1O)CO[C@H]1[C@@H]([C@H](C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1)O)N=C(O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZDZMLVPSYYRJNI-CYQYEHMMSA-N 0.000 abstract 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Abstract
El uso de un oligosacárido seleccionado de entre el grupo consistente en la lacto-N-tetraosa, la lacto-Nneotetraosa, la lacto-N-hexaosa, lacto-N-neohexaosa, la para-lacto-N-hexaosa, la para-lacto-N-neohexaosa, la lacto- N-octaosa, la lacto-N-neooctaosa, la iso-lacto-N-octaosa, la para-lacto-N-octaosa y la lacto-N-decaosa en la elaboración de un medicamento para niños pequeños lactantes, o en la elaboración de una composición nutricional terapéutica para niños pequeños lactantes, para modular el sistema inmune de un niño pequeño neonato, para estimular el desarrollo, en las primeras semanas de la vida del niño pequeño lactante, de una microbiota intestinal beneficiosa, comparable con la que se encuentra en los niños pequeños lactantes alimentados dándoles el pecho, en donde, el medicamento o la composición nutricional terapéutica, se administra, al niño pequeño lactante, inmediatamente después del parto, y después de éste, durante un transcurso de tiempo de por lo menos 2 meses.
Description
E08848466
22-01-2015
Continuación tabla
- Nutriente
- Por 100 kcal Por litro
- P (mg)
- 31 210
- Mg (mg)
- 7 50
- Mn (µg)
- 8 50
- Se (µg)
- 2 13
- Vitamina A (µg RE)
- 105 700
- Vitamina D (µg)
- 1,5 10
- Vitamina E (mg TE)
- 0,8 5,4
- Vitamina K1 (µg)
- 8 54
- Vitamina C (mg)
- 10 67
- Vitamina B1 (mg)
- 0,07 0,47
- Vitamina B2 (mg)
- 0,15 1,0
- Niacina (mg)
- 1 6,7
- Vitamina B6 (mg)
- 0,075 0,50
- Ácido fólico (µg)
- 9 60
- Ácido pantoténico (mg)
- 0,45 3
- Vitamina B12 (µg)
- 0,3 2
- Biotina (µg)
- 2,2 15
- Colina (mg)
- 10 67
- Fe (mg)
- 1,2 8
- I (µg)
- 15 100
- Cu (mg)
- 0,06 0,4
- Zn (mg)
- 0,75 5
- LNnT (mg)
- 37 250
8
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07120265 | 2007-11-08 | ||
| EP07120265 | 2007-11-08 | ||
| PCT/EP2008/065143 WO2009060073A1 (en) | 2007-11-08 | 2008-11-07 | Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2528469T3 true ES2528469T3 (es) | 2015-02-10 |
Family
ID=39111780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08848466.2T Active ES2528469T3 (es) | 2007-11-08 | 2008-11-07 | Uso de oligosacáridos que contienen N-acetil-lactosamida para la maduración de las respuestas inmunes en neonatos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100233198A1 (es) |
| EP (1) | EP2217246B1 (es) |
| CN (1) | CN101909636A (es) |
| AU (1) | AU2008324105B2 (es) |
| BR (1) | BRPI0820175B8 (es) |
| CA (1) | CA2705014A1 (es) |
| ES (1) | ES2528469T3 (es) |
| MX (1) | MX2010005132A (es) |
| MY (1) | MY159076A (es) |
| PL (1) | PL2217246T3 (es) |
| PT (1) | PT2217246E (es) |
| RU (1) | RU2486904C2 (es) |
| SG (1) | SG185948A1 (es) |
| WO (1) | WO2009060073A1 (es) |
| ZA (1) | ZA201004053B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2465509A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
| EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
| EP2454948A1 (en) | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
| NZ612472A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
| MX338174B (es) | 2010-12-31 | 2016-04-06 | Abbott Lab | Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios. |
| US9539269B2 (en) | 2010-12-31 | 2017-01-10 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
| CN103391783A (zh) | 2010-12-31 | 2013-11-13 | 雅培制药有限公司 | 使用人乳寡糖改善呼吸道健康的方法 |
| NZ612455A (en) * | 2010-12-31 | 2015-02-27 | Abbott Lab | Human milk oligosaccharides to promote growth of beneficial bacteria |
| EP3338784B1 (en) * | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
| MY166945A (en) | 2010-12-31 | 2018-07-25 | Abbott Lab | Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof |
| JP2014516589A (ja) | 2011-06-20 | 2014-07-17 | エイチ．ジェイ．ハインツ カンパニー | プロバイオティック組成物及び方法（ｐｒｏｂｉｏｔｉｃｃｏｍｐｏｓｉｔｉｏｎａｎｄｍｅｔｈｏｄｓ） |
| CA2842672A1 (en) | 2011-07-22 | 2013-01-31 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| SG2014013478A (en) * | 2011-08-29 | 2014-05-29 | Abbott Lab | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| CN103889240B (zh) * | 2011-10-18 | 2016-09-14 | 雀巢产品技术援助有限公司 | 用于增加胰岛素敏感性和/或降低胰岛素抵抗性的组合物 |
| EP2798069B1 (en) * | 2011-12-15 | 2017-03-29 | Washington University | Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection |
| CN104363962A (zh) * | 2012-03-27 | 2015-02-18 | 雅培制药有限公司 | 用于使用人乳寡糖调节细胞介导的免疫的方法 |
| CA2942732C (en) * | 2014-04-08 | 2023-01-03 | Abbott Laboratories | Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides |
| WO2016139328A1 (en) * | 2015-03-05 | 2016-09-09 | Nestec S.A. | Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children |
| WO2017021476A1 (en) * | 2015-08-04 | 2017-02-09 | Nestec S.A. | Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants |
| CN109414447A (zh) * | 2016-06-24 | 2019-03-01 | 格礼卡姆股份公司 | 包括hmo的组合物、其制备和用于预防和/或治疗病毒和/或细菌感染的用途 |
| AU2017307455B2 (en) | 2016-08-04 | 2023-07-06 | Société des Produits Nestlé S.A. | Nutritional compositions with 2FL and LNnT for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis |
| CN107955082B (zh) * | 2017-12-11 | 2019-05-10 | 江南大学 | 幽门螺旋杆菌脂多糖外核心八糖的制备方法 |
| CN116249537A (zh) | 2020-10-16 | 2023-06-09 | 雀巢产品有限公司 | 婴儿或幼儿配方食品 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE462134B (sv) * | 1987-10-22 | 1990-05-14 | Biocarb Ab | Livsmedel innehaallande lacto-n-tetraos och foerfarande foer dess framstaellning |
| WO1991016449A1 (en) * | 1990-04-16 | 1991-10-31 | The Trustees Of The University Of Pennsylvania | Saccharide compositions, methods and apparatus for their synthesis |
| US6204431B1 (en) * | 1994-03-09 | 2001-03-20 | Abbott Laboratories | Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk |
| US5906982A (en) * | 1997-03-31 | 1999-05-25 | Abbott Laboratories | Nutritional formulations containing Lacto-N-neoTetraose |
| US6045854A (en) * | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
| DE19958985A1 (de) * | 1999-12-07 | 2001-06-13 | Nutricia Nv | Oligosaccharidmischung |
| EP1062873A1 (en) * | 1999-12-13 | 2000-12-27 | N.V. Nutricia | Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate |
| FI20010118A (fi) * | 2001-01-19 | 2002-07-20 | Carbion Oy | Uudet helicobacter pylori reseptorit ja niiden käyttö |
| DE10147100A1 (de) * | 2001-09-25 | 2003-04-17 | Numico Res B V | Antiinfektive Kohlenhydrate |
| EP1531832B1 (en) * | 2002-06-28 | 2009-04-15 | Glykos Finland Oy | Therapeutic compositions for use in prophylaxis or treatment of diarrheas |
| ES2416287T3 (es) * | 2003-06-23 | 2013-07-31 | Nestec S.A. | Empleo de una fórmula nutritiva para la función óptima de la barrera intestinal |
| ES1056525Y (es) * | 2004-01-13 | 2004-07-16 | Perez Alfredo Pineiro | Halador de tres rodillos para redes y aparejos de pesca. |
| US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| EP1714660A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
| PT1993577E (pt) * | 2006-03-10 | 2014-05-27 | Nutricia Nv | Uso de sacarídeos não digestivos para proporcionar a uma criança o melhor começo após o nascimento |
| ATE498629T1 (de) * | 2006-03-13 | 2011-03-15 | Glycom Aps | Neue lactosaminderivate |
| US8197872B2 (en) * | 2007-05-17 | 2012-06-12 | The Regents Of The University Of California | Human milk oligosaccharides to promote growth of beneficial gut bacteria |
-
2008
- 2008-11-07 CA CA2705014A patent/CA2705014A1/en not_active Abandoned
- 2008-11-07 US US12/741,997 patent/US20100233198A1/en not_active Abandoned
- 2008-11-07 RU RU2010123176/15A patent/RU2486904C2/ru active
- 2008-11-07 MY MYPI2010002042A patent/MY159076A/en unknown
- 2008-11-07 CN CN2008801240700A patent/CN101909636A/zh active Pending
- 2008-11-07 EP EP08848466.2A patent/EP2217246B1/en not_active Revoked
- 2008-11-07 AU AU2008324105A patent/AU2008324105B2/en active Active
- 2008-11-07 PL PL08848466T patent/PL2217246T3/pl unknown
- 2008-11-07 BR BRPI0820175A patent/BRPI0820175B8/pt active IP Right Grant
- 2008-11-07 SG SG2012081311A patent/SG185948A1/en unknown
- 2008-11-07 MX MX2010005132A patent/MX2010005132A/es active IP Right Grant
- 2008-11-07 WO PCT/EP2008/065143 patent/WO2009060073A1/en active Application Filing
- 2008-11-07 PT PT88484662T patent/PT2217246E/pt unknown
- 2008-11-07 ES ES08848466.2T patent/ES2528469T3/es active Active
-
2010
- 2010-06-07 ZA ZA2010/04053A patent/ZA201004053B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010005132A (es) | 2010-06-02 |
| AU2008324105B2 (en) | 2014-01-30 |
| US20100233198A1 (en) | 2010-09-16 |
| CN101909636A (zh) | 2010-12-08 |
| CA2705014A1 (en) | 2009-05-14 |
| SG185948A1 (en) | 2012-12-28 |
| AU2008324105A1 (en) | 2009-05-14 |
| EP2217246A1 (en) | 2010-08-18 |
| RU2486904C2 (ru) | 2013-07-10 |
| BRPI0820175A2 (pt) | 2015-06-16 |
| PL2217246T3 (pl) | 2015-06-30 |
| RU2010123176A (ru) | 2011-12-20 |
| BRPI0820175B8 (pt) | 2022-11-22 |
| ZA201004053B (en) | 2016-08-31 |
| EP2217246B1 (en) | 2014-12-17 |
| WO2009060073A1 (en) | 2009-05-14 |
| PT2217246E (pt) | 2015-02-10 |
| BRPI0820175B1 (pt) | 2019-02-12 |
| MY159076A (en) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528469T3 (es) | Uso de oligosacáridos que contienen N-acetil-lactosamida para la maduración de las respuestas inmunes en neonatos | |
| ES2559381T3 (es) | Composición para su uso en la promoción del crecimiento de hueso sano y/o en la prevención y/o tratamiento de osteopatía | |
| JP6852980B2 (ja) | 低カロリー高タンパク質の栄養組成物及び該栄養組成物を用いる方法 | |
| JP5787480B2 (ja) | 維持のための長期経腸栄養供給 | |
| TWI633882B (zh) | 適用於提高女性生育力的組合物 | |
| US20020044961A1 (en) | Nutritional formulations | |
| US20060099239A1 (en) | Dietary supplement for promoting removal of heavy metals from the body | |
| EP2773361B1 (en) | Method for improving executive function | |
| US11318150B1 (en) | Vitamin supplement compositions with enhanced bioavailability | |
| US20050276838A1 (en) | Composition and method for viral inhibition | |
| MXPA06013676A (es) | Formulaciones nutricionales. | |
| US10039805B1 (en) | Infant formulas having vitamin complexes with enhanced bioavailability | |
| BR0115451A (pt) | Suplemento a ser administrado por via enteral para a alimentação parenteral ou alimentação enteral/oral parcial em doentes crìticos, doentes crÈnicos e com nutrição deficiente | |
| US11197917B2 (en) | Formulations for nutritional support in subjects in need thereof | |
| US8791065B2 (en) | Low-concentration nutritional composition | |
| US20150132273A1 (en) | Nutritional Compositions and Methods for Treating Cognitive Impairment | |
| US20050271600A1 (en) | Fiber supplement | |
| Hardy et al. | Nutraceuticals: a pharmaceutical viewpoint: I | |
| JP6907118B2 (ja) | 経口送達製品 | |
| RU2013124962A (ru) | Композиции и способы доставки питательных веществ | |
| JP6453534B2 (ja) | 脂質代謝促進剤 | |
| RU2016144680A (ru) | Композиция для улучшения умственных способностей | |
| ES2862149T3 (es) | Polifenoles de cacao y fibra dietética soluble para uso en el tratamiento o prevención de trastornos asociados a un número superior al normal de granulocitos en un tejido | |
| Becerra-Granados et al. | Interdisciplinary management of infantile colic | |
| JP2007210907A (ja) | 消化管機能改善用組成物 |